Bayer: One Legal Victory, Two New Threats, and a Divided Analyst Community

Bayer shares surge 54% after Supreme Court strikes down Roundup lawsuits, but overbought RSI of 84.4 and potential U.S. tariffs on German drugs cloud the outlook.

A fresh trade storm is gathering over Bayer just as investors celebrate the company's landmark win at the U.S. Supreme Court. The U.S. Trade Representative is probing German drug pricing, with a hearing scheduled for September 22, 2026, and potential retaliatory tariffs on German pharmaceutical imports could start as early as July 31. While the investigation is still in its early stages, it adds an unwelcome layer of uncertainty to a stock that has already rocketed 54% in the past month alone.

The legal victory itself was decisive. The Supreme Court struck down a key legal underpinning for thousands of Roundup weedkiller lawsuits, dramatically reducing Bayer's tail-risk exposure. Shares jumped 7.27% on the day to €52.24, narrowly missing the 52-week high. The ruling hands Bayer a stronger hand in ongoing settlement negotiations, which are expected to run into the billions. Bank of America described the decision as a "big win" for the long-running litigation saga.

Yet the euphoria has pushed the stock into technically extreme territory. The 14-day Relative Strength Index stands at 84.4 — far above the 70 threshold that signals overbought conditions. The share price now trades roughly 35% above its 50-day moving average of €38.58, a gap that historically invites profit-taking. "The rally has already priced in much of the legal relief," warned AlphaValue/Baader Europe in a downgrade to Reduce on June 26, despite raising its price target. That single red flag, however, is matched by multiple reaffirmations of confidence. UBS confirmed its Buy rating the same day, while the DZ Bank and Bank of America also remain bullish.

The tension between the bullish and bearish cases is stark. On the bull side, Bayer's first-quarter earnings per share more than doubled to €2.81 from €1.32 a year earlier. New pharmaceutical approvals and rising demand for crop protection chemicals are providing operational ammunition. The market now capitalizes the company at €46.17 billion, a 94% leap from its €25.09 low twelve months ago. For optimists, the Supreme Court ruling is the catalyst that unlocks years of legal overhang, paving the way for a cleaner growth narrative.

Bears counter that the technical warnings are flashing red. An RSI of 84.4, coupled with annualized volatility of 59.44%, makes sharp reversals historically probable. Revenue slipped slightly to just over €13.4 billion in the first quarter, and high debt levels remain a drag on the balance sheet. The final settlement with Roundup plaintiffs has yet to be signed off by the court, leaving room for new legal arguments. AlphaValue/Baader's assessment that "from here, the upside looks limited" captures the valuation concern.

The near-term outlook hinges on two dates beyond the immediate Supreme Court glow. First, any U.S. tariffs could materialize as soon as July 31, testing whether the stock's elevated optimism can withstand a real trade headwind. Second, the USTR hearing on September 22 will clarify whether the investigation leads to punitive measures. In between, second-quarter results due in August will show whether operational performance backs up the share price gains. Until then, the rally's staying power rests on the hope that one legal victory can outweigh two emerging threats — and that the analysts who remain bullish are reading the tea leaves correctly.